Wegovy's Oral Pill Takes Sixty-Five Percent of New U.S. Obesity Prescriptions in Three Months
Novo Nordisk Q1 — pill sales beat consensus by 95%, 1.3M scripts, 65% of new U.S. obesity starts, stock +6.7% in Copenhagen, full-year guidance raised.
The news. The narrative. The timeline.
Bureau: Chicago
Novo Nordisk Q1 — pill sales beat consensus by 95%, 1.3M scripts, 65% of new U.S. obesity starts, stock +6.7% in Copenhagen, full-year guidance raised.
A Cochrane meta-analysis says anti-amyloid drugs do not work, but UKDRI calls it weakened by lumping five failed drugs with two approved ones the same week Health Canada cleared Kisunla.
A 95,490-person within-person study finds the depression and anxiety benefit is semaglutide-specific, not a class effect — as the Wegovy pill scales without psychiatric labeling.
The morning after Tuesday's compressed Cinco de Mayo cycle, the durable story is cultural appropriation — not restaurant margins — with Sinaloa's Bonilla Day 3 running the parallel sovereignty frame.
Utah's measles outbreak now stands at 638 cases — 441 from 2026 — with the PAHO November regional-elimination review running and no federal containment posture from CDC or HHS.
Foundayo's third-week U.S. prescriptions hit 5,612 against oral Wegovy's 134,000 the same week — a 24x gap that surfaces actual launch trajectory, not the demographic-winter narrative.
Idaho's H5N1 outbreak vector remains officially unnamed as USDA keeps loosening interstate dairy testing — the case-vector question is now the federal policy question.
The pediatrics rebukes of the CDC's autism-vaccine page now have a Science journal study quantifying the trust erosion in federal health guidance.